First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

被引：0
|
作者：
Tripathy, Debu
Sohn, Joohyuk
Im, Seock-Ah
Colleoni, Marco
Franke, Fabio
Bardia, Aditya
Harbeck, Nadia
Hurvitz, Sara
Chow, Louis
Lee, Keun Seok
Campos-Gomez, Saul
Vazquez, Rafael Villanueva
Jung, Kyung Hae
Carlson, Gary
Hughes, Gareth
Diaz-Padilla, Ivan
Germa, Caroline
Hirawat, Samit
Lu, Yen-Shen
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
[4] Ist Europeo Oncol, Unita Ric Senol Med, Milan, Italy
[5] CACONIjui, Hosp Caridade Ijui, Ijui, RS, Brazil
[6] Havard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[7] Univ Munich LMU, Breast Ctr, Munich, Germany
[8] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[9] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China
[10] Res Inst & Hosp, Natl Canc Ctr, Goyang, South Korea
[11] Inst Seguridad Social Estado Mexico & Municipios, Ctr Oncol Estatal, Toluca, Mexico
[12] Hosp Moises Broggi, Inst Catala Oncol, Barcelona, Spain
[13] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[14] Nova Pharmaceut Corp, E Hanover, NJ USA
[15] Novartis Pharma AG, Basel, Switzerland
[16] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-05
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase Ib study of ribociclib plus letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA
    Yap, Yoon Sim
    Ito, Yoshinori
    Suarez-Vizcarra, Jose
    Liu, Xiaochun
    Han, Yu
    Germa, Caroline
    Chiu, Joanne
    CANCER RESEARCH, 2018, 78 (04)
  • [42] Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer.
    Gradishar, W. J.
    Chia, S.
    Piccart-Gebhart, M. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S8 - S9
  • [43] A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole (BioItaLEE)
    De laurentiis, M.
    Arpino, G.
    Bianchini, G.
    Malorni, L.
    Castelletti, D.
    De Vecchi, R.
    Grasso, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting
    Decker, Thomas
    Zaiss, Matthias
    Klein, Dunja
    Hahn, Antje
    Hagen, Volker
    La Rosee, Paul
    Liersch, Ruediger
    Wolff, Thomas
    Hillebrand, Larissa E.
    Niemeier, Beate
    Lennartz, Carolin
    Chiabudini, Marco
    Bengsch, Fee
    Indorf, Martin
    Marschner, Norbert
    BREAST CARE, 2024, 19 (01) : 49 - 61
  • [45] A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
    Shao, Hanqiao
    Zhao, Mingye
    Guan, Ai-Jia
    Shao, Taihang
    Zhou, Dachuang
    Yu, Guo
    Tang, Wenxi
    BMC MEDICINE, 2024, 22 (01)
  • [46] First-line ribociclib plus letrozole in postmenopausal Asian women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
    Yap, Y. S.
    Tseng, L-M.
    Blackwell, K. L.
    Cameron, D.
    Foo, S.
    Sriuranpong, V.
    Huang, C-S.
    Chao, T-Y.
    Kim, T-Y.
    Chen, S-C.
    Jung, K. H.
    Lee, K. S.
    Sohn, J-H.
    Kim, J. H.
    Hou, M-F.
    Han, Y.
    Souami, F.
    Dhuria, S.
    Miller, M.
    Verma, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
    Hanqiao Shao
    Mingye Zhao
    Ai-Jia Guan
    Taihang Shao
    Dachuang Zhou
    Guo Yu
    Wenxi Tang
    BMC Medicine, 22
  • [48] Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
    Dent, S.
    Cortes, J.
    Im, Y-H
    Dieras, V
    Harbeck, N.
    Krop, I. E.
    Wilson, T. R.
    Cui, N.
    Schimmoller, F.
    Hsu, J. Y.
    He, J.
    De Laurentiis, M.
    Sousa, S.
    Drullinsky, P.
    Jacot, W.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 197 - 207
  • [49] PATHWAY: Asian, multicenter, phase 3 trial of tamoxifen with or without palbociclib goserelin in women with hormone receptor -positive, HER2negative advanced or metastatic breast cancer
    Noguchi, E.
    Hata, T.
    Nakamura, K.
    Kuchiba, A.
    Hayashi, M.
    Hamada, A.
    Yonemori, K.
    Sohn, J.
    Lu, Y-S
    Yap, Y-S
    Fujiwara, Y.
    Tamura, K.
    CANCER RESEARCH, 2019, 79 (04)
  • [50] Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial
    Baselga, Jose
    Piccart, Martine
    Rugo, Hope
    Chen, David
    Burris, Howard A.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra
    Deleu, Inas
    Shtivelband, Mikhail
    Provencher, Louise
    Derti, Adnan
    Huang, Alan
    McDonald, Rob
    Kalfoglou, Creton
    Robinson, Douglas
    Taran, Tetiana
    Sahmoud, Tarek
    Lebwohl, David
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2013, 73 (08)
12345